Assessment report - European Medicines Agency · PPK population pharmacokine tics . PR Partial...

download Assessment report - European Medicines Agency · PPK population pharmacokine tics . PR Partial response . PS performance status . Assessment report EMA/CHMP/271863/2017 Page 5/89

If you can't read please download the document

CHMP assessment report - ema.europa.eu · 20 February 2014 . EMA/CHMP/175692/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . DuoResp Spiromax

CHMP assessment report - ema.europa.eu · 20 February 2014 . EMA/CHMP/175692/2014 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . DuoResp Spiromax

CHMP assessment report · Bretaris Genuair CHMP assessment report EMA/CHMP/303918/2012 Page 6/76. Licensing status . A new application was filed in the US (23 June 2011) and Switzerland

CHMP assessment report · Bretaris Genuair CHMP assessment report EMA/CHMP/303918/2012 Page 6/76. Licensing status . A new application was filed in the US (23 June 2011) and Switzerland

CHMP extension of indication variation assessment …...London, 25 April 2014 EMA/CHMP/220738/2014 Committee for Medicinal Products for Human Use (CHMP) CHMP extension of indication

CHMP extension of indication variation assessment …...London, 25 April 2014 EMA/CHMP/220738/2014 Committee for Medicinal Products for Human Use (CHMP) CHMP extension of indication

CHMP ASSESSMENT REPORT FOR Vedrop · Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted . ... • The Applicant submitted

CHMP ASSESSMENT REPORT FOR Vedrop · Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted . ... • The Applicant submitted

CHMP extension of indication variation assessment report · CHMP extension of indication variation assessment report EMA/CHMP/647625/2019 Page 8/88 The majority of EGFR mutations

CHMP extension of indication variation assessment report · CHMP extension of indication variation assessment report EMA/CHMP/647625/2019 Page 8/88 The majority of EGFR mutations

CHMP ASSESSMENT REPORT Myfenax - ema.europa.eu

CHMP ASSESSMENT REPORT Myfenax - ema.europa.eu

CHMP assessment report...22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab

CHMP assessment report...22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab

CHMP assessment report€¦ · CHMP assessment report EMA/CHMP/208477/2013 Page 9/136 September 2012. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members

CHMP assessment report€¦ · CHMP assessment report EMA/CHMP/208477/2013 Page 9/136 September 2012. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members

chmp Assessment Report Firazyr - European€¦ · Assessment Report as adopted by the CHMP with . all information of a commercially confidential nature deleted. TABLE OF CONTENTS

chmp Assessment Report Firazyr - European€¦ · Assessment Report as adopted by the CHMP with . all information of a commercially confidential nature deleted. TABLE OF CONTENTS

CHMP assessment report on extension of marketing ... · CHMP assessment report on extension of marketing authorisation and an extension of indication variation . Dupixent . International

CHMP assessment report on extension of marketing ... · CHMP assessment report on extension of marketing authorisation and an extension of indication variation . Dupixent . International

CHMP assessment report - European Medicines Agency...Ryzodeg CHMP assessment report Page 6/151 development with specific focus on the carcinogenicity assessment. The agencies confirmed

CHMP assessment report - European Medicines Agency...Ryzodeg CHMP assessment report Page 6/151 development with specific focus on the carcinogenicity assessment. The agencies confirmed

CHMP Type II variation assessment report...SU Sulfonylurea T2DM Type 2 diabetes mellitus TZD Thiazolidinedione US United States CHMP Type II variation assessment report EMA/CHMP/432717/2013

CHMP Type II variation assessment report...SU Sulfonylurea T2DM Type 2 diabetes mellitus TZD Thiazolidinedione US United States CHMP Type II variation assessment report EMA/CHMP/432717/2013

CHMP assessment report · 25 July 2013 . EMA/CHMP/456924/2013 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . Xoterna Breezhaler . International non-proprietary

CHMP assessment report · 25 July 2013 . EMA/CHMP/456924/2013 . Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report . Xoterna Breezhaler . International non-proprietary

CHMP assessment report - European Medicines Agency...CHMP assessment report EMA/CHMP/207158/2013 Page 7/136 No 847/2000, the applicant did not submit a critical report addressing the

CHMP assessment report - European Medicines Agency...CHMP assessment report EMA/CHMP/207158/2013 Page 7/136 No 847/2000, the applicant did not submit a critical report addressing the

CHMP ASSESSMENT REPORT FOR INTELENCE · CHMP ASSESSMENT REPORT FOR INTELENCE International Nonproprietary Name: etravirine Procedure No. EMEA/H/C/000900 ... the criteria for accelerated

CHMP ASSESSMENT REPORT FOR INTELENCE · CHMP ASSESSMENT REPORT FOR INTELENCE International Nonproprietary Name: etravirine Procedure No. EMEA/H/C/000900 ... the criteria for accelerated

Assessment report for paediatric studies submitted ... · Assessment report as adopted by the CHMP with all information of a commercially confidential ... PPK Per-protocol pharmacokinetic

Assessment report for paediatric studies submitted ... · Assessment report as adopted by the CHMP with all information of a commercially confidential ... PPK Per-protocol pharmacokinetic

CHMP assessment report 15 October 2020 EMA/584450/2020 ...

CHMP assessment report 15 October 2020 EMA/584450/2020 ...

CHMP ASSESSMENT REPORT FOR Nymusa€¦ · CHMP ASSESSMENT REPORT FOR Nymusa International Nonproprietary Name: caffeine Procedure No. EMEA/H/C/001014 Assessment Report as adopted

CHMP ASSESSMENT REPORT FOR Nymusa€¦ · CHMP ASSESSMENT REPORT FOR Nymusa International Nonproprietary Name: caffeine Procedure No. EMEA/H/C/001014 Assessment Report as adopted

CHMP assessment report for paediatric use studies ......21 November 2013 EMA/CHMP/780068/2013 Committee for Medicinal Products for Human Use (CHMP) Synagis (Palivizumab) Procedure

CHMP assessment report for paediatric use studies ......21 November 2013 EMA/CHMP/780068/2013 Committee for Medicinal Products for Human Use (CHMP) Synagis (Palivizumab) Procedure

CHMP variation assessment report - Europa

CHMP variation assessment report - Europa